RadNet’s Wholly-Owned Subsidiary, DeepHealth, Completes Acquisition of iCAD
RadNet (NASDAQ:RDNT) has completed the acquisition of iCAD (NASDAQ:ICAD), a global leader in AI-powered breast health solutions, through its wholly-owned subsidiary DeepHealth. The strategic acquisition integrates iCAD's extensive AI portfolio for breast cancer detection with DeepHealth's screening solutions, expanding their reach to over 10 million mammograms annually.
iCAD's technology portfolio, deployed in more than 50 countries across 1,500+ healthcare provider locations, includes solutions for breast cancer detection, risk evaluation, breast density, and arterial calcification assessment. The combination aims to enhance AI model performance and accelerate the adoption of advanced breast cancer screening technologies worldwide, particularly in underserved communities.
RadNet (NASDAQ:RDNT) ha completato l'acquisizione di iCAD (NASDAQ:ICAD), leader globale nelle soluzioni per la salute del seno basate sull'intelligenza artificiale, tramite la sua controllata al 100% DeepHealth. Questa acquisizione strategica integra l'ampio portafoglio di soluzioni AI di iCAD per la rilevazione del cancro al seno con le soluzioni di screening di DeepHealth, estendendo la loro copertura a oltre 10 milioni di mammografie all'anno.
Il portafoglio tecnologico di iCAD, utilizzato in più di 50 paesi e in oltre 1.500 strutture sanitarie, comprende soluzioni per la rilevazione del cancro al seno, la valutazione del rischio, la densità mammaria e la valutazione della calcificazione arteriosa. Questa unione mira a migliorare le prestazioni dei modelli AI e a velocizzare l'adozione di tecnologie avanzate per lo screening del cancro al seno a livello globale, con particolare attenzione alle comunità meno servite.
RadNet (NASDAQ:RDNT) ha completado la adquisición de iCAD (NASDAQ:ICAD), líder mundial en soluciones de salud mamaria impulsadas por inteligencia artificial, a través de su subsidiaria de propiedad total DeepHealth. Esta adquisición estratégica integra el extenso portafolio de IA de iCAD para la detección del cáncer de mama con las soluciones de detección de DeepHealth, ampliando su alcance a más de 10 millones de mamografías anuales.
El portafolio tecnológico de iCAD, desplegado en más de 50 países y en más de 1,500 ubicaciones de proveedores de salud, incluye soluciones para la detección del cáncer de mama, evaluación de riesgos, densidad mamaria y evaluación de calcificación arterial. La combinación busca mejorar el rendimiento de los modelos de IA y acelerar la adopción de tecnologías avanzadas de detección del cáncer de mama en todo el mundo, especialmente en comunidades desatendidas.
RadNet (NASDAQ:RDNT)는 전액 출자 자회사 DeepHealth를 통해 인공지능 기반 유방 건강 솔루션의 글로벌 선도기업인 iCAD (NASDAQ:ICAD)의 인수를 완료했습니다. 이번 전략적 인수는 iCAD의 광범위한 유방암 탐지 AI 포트폴리오와 DeepHealth의 스크리닝 솔루션을 통합하여 연간 1,000만 건 이상의 유방촬영술에 대한 접근성을 확대합니다.
iCAD의 기술 포트폴리오는 50개국 이상의 1,500개 이상의 의료 제공 장소에서 적용되고 있으며, 유방암 탐지, 위험 평가, 유방 밀도 및 동맥 석회화 평가 솔루션을 포함합니다. 이번 통합은 AI 모델 성능을 향상시키고 전 세계 특히 의료 서비스가 부족한 지역에서 첨단 유방암 스크리닝 기술의 도입을 가속화하는 것을 목표로 합니다.
RadNet (NASDAQ:RDNT) a finalisé l'acquisition de iCAD (NASDAQ:ICAD), un leader mondial des solutions de santé mammaire basées sur l'intelligence artificielle, via sa filiale en propriété exclusive DeepHealth. Cette acquisition stratégique intègre le vaste portefeuille d'IA d'iCAD pour la détection du cancer du sein avec les solutions de dépistage de DeepHealth, étendant leur portée à plus de 10 millions de mammographies par an.
Le portefeuille technologique d'iCAD, déployé dans plus de 50 pays et dans plus de 1 500 établissements de santé, comprend des solutions pour la détection du cancer du sein, l'évaluation des risques, la densité mammaire et l'évaluation de la calcification artérielle. Cette combinaison vise à améliorer les performances des modèles d'IA et à accélérer l'adoption des technologies avancées de dépistage du cancer du sein dans le monde, en particulier dans les communautés mal desservies.
RadNet (NASDAQ:RDNT) hat die Übernahme von iCAD (NASDAQ:ICAD), einem weltweit führenden Anbieter von KI-gestützten Lösungen für die Brustgesundheit, über seine hundertprozentige Tochtergesellschaft DeepHealth abgeschlossen. Die strategische Akquisition integriert iCADs umfangreiches KI-Portfolio zur Brustkrebs-Erkennung mit den Screening-Lösungen von DeepHealth und erweitert so die Reichweite auf über 10 Millionen Mammographien jährlich.
Das Technologieportfolio von iCAD, das in mehr als 50 Ländern an über 1.500 Standorten von Gesundheitsdienstleistern eingesetzt wird, umfasst Lösungen zur Brustkrebs-Erkennung, Risikobewertung, Brustdichte und Beurteilung von arteriellen Verkalkungen. Die Kombination zielt darauf ab, die Leistung der KI-Modelle zu verbessern und die Einführung fortschrittlicher Brustkrebs-Screening-Technologien weltweit, insbesondere in unterversorgten Gemeinschaften, zu beschleunigen.
- Integration expands reach to over 10 million mammograms annually across 50+ countries
- Access to iCAD's established network of 1,500+ healthcare provider locations
- Enhanced AI capabilities through combined technology portfolios and datasets
- Expanded market presence in breast cancer detection and screening solutions
- Integration challenges and costs associated with merging technologies
- Potential regulatory compliance complexities across multiple jurisdictions
Insights
RadNet's DeepHealth acquisition of iCAD creates an AI powerhouse in breast cancer detection, expanding global reach to 10M+ mammograms annually.
This strategic acquisition represents a significant consolidation in the AI-powered breast health solutions market. RadNet's subsidiary DeepHealth is acquiring iCAD, bringing together complementary technologies that address the entire breast cancer screening and diagnostic pathway.
The combined entity will integrate iCAD's extensive AI portfolio—covering breast cancer detection, risk evaluation, density assessment, and arterial calcification analysis—with DeepHealth's existing solutions. This creates a comprehensive suite of AI tools that could meaningfully improve both cancer detection rates and workflow efficiency.
What makes this deal particularly valuable is iCAD's established global footprint in over 50 countries and an installed base exceeding 1,500 healthcare provider locations. This immediately scales DeepHealth's impact to potentially over 10 million mammograms annually—a substantial increase in market penetration that would have taken years to achieve organically.
The acquisition addresses several critical challenges in breast cancer screening: improving early detection accuracy, managing large-scale screening programs, and extending advanced diagnostic capabilities to underserved communities. By combining datasets and algorithms, the merged entity can potentially develop more robust AI models with better performance characteristics.
For RadNet, this acquisition strengthens its Digital Health segment's competitive position against other healthcare AI providers while creating new revenue opportunities through an expanded global customer base. The deal aligns with the broader healthcare industry trend toward AI-augmented clinical decision support systems that can address radiologist shortages while maintaining or improving diagnostic accuracy.
- Acquisition contributes iCAD's commercial, technology, and regulatory capabilities
- The acquisition positions DeepHealth with an industry-leading suite of AI-powered breast cancer image interpretation and workflow solutions
- The combination is expected to provide acceleration of AI adoption and expanded worldwide access to advanced breast cancer screening and diagnosis technologies
LOS ANGELES, July 17, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, announced today that it has completed the acquisition of iCAD, Inc. (NASDAQ: ICAD) (“iCAD”), a global leader in AI-powered breast health solutions. The integration of iCAD's complementary commercial, technology, and regulatory capabilities into DeepHealth advances DeepHealth’s mission to address clinical and operational challenges in screening and diagnosis by harnessing the power of AI and imaging.
Kees Wesdorp, President and CEO of RadNet’s Digital Health segment, commented, “We are excited to welcome the iCAD team to DeepHealth. The integration of iCAD further empowers DeepHealth to meet the real-world clinical needs of today, from improving the accuracy and early detection of breast cancer to orchestrating large-scale screening programs, while shaping the future of breast cancer management. Our combined capabilities position us for accelerated growth and rapid delivery of transformative, AI-powered population health solutions.”
iCAD’s extensive AI portfolio—including breast cancer detection, risk evaluation, breast density, and breast arterial calcification assessment—is deployed in more than 50 countries. This portfolio will be integrated with DeepHealth’s end-to-end screening and diagnostic solutions, further improving both cancer detection rates and workflow efficiency. By uniting complementary technologies and datasets, the combined portfolio can further enhance AI model performance and enable the delivery of a comprehensive suite of AI-powered image interpretation and workflow solutions that address real-world clinical needs across the cancer screening and detection pathways.
With expanded market access through iCAD's installed base of over 1,500 healthcare provider locations worldwide, this strategic acquisition enables DeepHealth to scale its impact to over 10 million mammograms annually. This global reach aims to accelerate AI adoption and screening compliance by bringing advanced AI-powered solutions to communities around the world, including those that are underserved.
About RadNet
RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 401 owned and/or operated outpatient imaging centers. RadNet’s imaging center markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 11,000 employees. For more information, visit http://www.radnet.com.
About DeepHealth
DeepHealth is a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for all companies within RadNet’s Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. Building on the strengths of the companies it has integrated and is rebranding (e.g., eRAD Radiology Information and Image Management Systems and Picture Archiving and Communication System, Aidence lung AI, DeepHealth, Kheiron, and iCAD breast AI, Quantib prostate and brain AI, and See-Mode thyroid and breast AI), DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in lung, breast, prostate, and brain health. At the heart of DeepHealth’s portfolio is a cloud-native operating system – DeepHealth OS – that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of radiologists at hundreds of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth’s human-centered, intuitive technology aims to push the boundaries of what’s possible in healthcare. https://deephealth.com/
RadNet Contact
Mark Stolper
Executive Vice President and Chief Financial Officer
310-445-2800
DeepHealth Contact
Andra Axente
Director of Communications
+31614440971
andra.axente@deephealth.com
Forward-Looking Statements
This communication contains certain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as: “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “outlook,” “plan,” “potential,” “possible,” “predict,” “project,” “seek, “should,” “target,” “will” or “would,” the negative of these words, and similar references to future periods. Examples of forward-looking statements include statements regarding the anticipated benefits of the acquisition, the impact of the acquisition on RadNet’s business and future financial and operating results and prospects and the amount and timing of synergies from the acquisition are based on the current estimates, assumptions and projections of RadNet, and are qualified by the inherent risks and uncertainties surrounding future expectations generally, all of which are subject to change. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties, many of which are beyond RadNet’s control.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations and assumptions regarding the future of RadNet’s business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of RadNet’s control. RadNet’s actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of various factors. None of RadNet, iCAD or any of their respective directors, executive officers, or advisors, provide any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur, or if any of them do occur, what impact they will have on the business, results of operations or financial condition of RadNet. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on RadNet’s business and the ability to realize the expected benefits of the acquisition. Risks and uncertainties that could cause results to differ from expectations include, but are not limited to: (1) the ability to recognize the anticipated benefits of the acquisition, which may be affected by, among other things, the ability of RadNet or iCAD to maintain relationships with its customers, patients, payers, physicians, and providers and retain its management and key employees, (2) the ability of RadNet to achieve the synergies contemplated by the acquisition or such synergies taking longer to realize than expected, (3) costs related to the acquisition, (4) the ability of RadNet to execute successfully its strategic plans, (5) the ability of RadNet to promptly and effectively integrate iCAD into its business, (6) the risk of litigation related to the acquisition, (7) the diversion of management’s time and attention from ordinary course business operations to integration matters, (8) the risk of legislative, regulatory, economic, competitive, and technological changes. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks, uncertainties and assumptions can be found in RadNet’s filings with the Securities and Exchange Commission (the “SEC”), including the risk factors discussed in RadNet’s most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q and future filings with the SEC.
Forward-looking statements included herein are made only as of the date hereof and, except as required by applicable law, RadNet does not undertake any obligation to update any forward-looking statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct any inaccuracies or omissions in them which become apparent. All forward-looking statements in this communication are qualified in their entirety by this cautionary statement.
FAQ
What companies are involved in the RadNet-iCAD acquisition?
How many mammograms will DeepHealth process after acquiring iCAD?
What is iCAD's current market presence before the RadNet acquisition?
What technologies does iCAD bring to the RadNet acquisition?
How will the RadNet-iCAD merger benefit healthcare delivery?
